JY
GPCR icon

Jeff Yass’s Structure Therapeutics GPCR Stock Holding History

Jeff Yass’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.57M Buy
122,344
+66,502
+119% +$2.94M ﹤0.01% 4111
2026
Q1 		$2.69M Buy
55,842
+46,843
+521% +$3.21M ﹤0.01% 5501
2025
Q4 		$626K Sell
8,999
-204,609
-96% -$8.35M ﹤0.01% 8283
2025
Q3 		$5.98M Buy
213,608
+137,806
+182% +$2.74M ﹤0.01% 3803
2025
Q2 		$1.57M Buy
75,802
+7,635
+11% +$168K ﹤0.01% 6318
2025
Q1 		$1.18M Sell
68,167
-36
-0.1% -$882 ﹤0.01% 6840
2024
Q4 		$1.85M Buy
68,203
+4,422
+7% +$157K ﹤0.01% 5498
2024
Q3 		$2.8M Sell
63,781
-55,837
-47% -$2.16M ﹤0.01% 4673
2024
Q2 		$4.7M Buy
119,618
+37,826
+46% +$1.55M ﹤0.01% 3543
2024
Q1 		$3.51M Buy
81,792
+70,090
+599% +$2.96M ﹤0.01% 4221
2023
Q4 		$477K Buy
+11,702
New +$671K ﹤0.01% 8788

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Jeff Yass's GPCR Position: Q2 2026 in Review

Jeff Yass increased its Structure Therapeutics (GPCR) stake by 119% in Q2 2026, buying an estimated $2.94M and bringing the position to 122,344 shares worth $6.57M. The position accounts for ﹤0.01% of the portfolio, ranked #4111.

Jeff Yass first reported a position in GPCR in Q4 2023 and has held it in 11 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Jeff Yass held 122,344 shares of Structure Therapeutics worth $6.57M as of Q2 2026.
  • Jeff Yass bought 66,502 Structure Therapeutics shares in Q2 2026, an estimated $2.94M.
  • Structure Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4111 holding.
  • Jeff Yass first reported a position in Structure Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.